TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05563402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atalante
Description: Atalante Gait training: Using the Atalante System (self-reliant walking system), participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute).
Study: NCT05400395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNX80
Description: GNX80 oral intake(BID) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral intake(BID) for 24 weeks
Study: NCT05619406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Riskometer Application
Description: The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Clinic Therapy
Description: After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.
Study: NCT04982978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PMT Threat Appraisal
Description: The first half of the PMT present video will include narration by Science Insider producer, Benji Jones, including dialogue regarding the risks associated with vaping by Chief Pediatric Pulmonology at the NYU Winthrop Hospital, Dr. Melodi Pirzada, and information on nicotine by the Director of Pediatric Pulmonology at NYU's Langone Hassenfeld Children's Hospital, Dr. Mikhail Kazachkov. The second half of the PMT present video will include personal experiences and narratives by students at the University of Utah with information regarding our current knowledge of vaping health effects through research by Dr. Sean Maddock and Dr. Sean Callahan from the University of Utah to highlight the susceptibility of vaping for a population of young adults in university.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General Nutrition and Lifestyle
Description: The first half of the PMT absent video will be presented by the Alliance for Aging Research, including an immersive video design, explaining the impact that nutrition may have as the participants age, reviewed by Dr. Steven Austad and Senior Nutritionist Johanna Dwyer. The second half of the PMT absent video will be presented by TED-Ed with narration by Addison Anderson, including a similar immersive video design, explaining how the food the participants eat may affect our brain and overall health. The nutrition and lifestyle information design will be administered as a control because it provides informative lifestyle choices regarding nutrition that can help promote the participants overall health without having an underlying link to vaping behaviour and its subsequent effect on the status of health.
Study: NCT05827575

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Vagal Nerve Stimulation
Description: stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagal Nerve Stimulation
Description: stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
Study: NCT05776316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Harm Reduction Intervention (IHRI)
Description: 8-week program targeting areas rooted in the 8 principles of harm reduction. Includes weekly education lessons and informed referrals to social service organizations.
Study: NCT06339203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrisept
Description: 450ml low concentration (0.05%) Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 450mL
Study: NCT04421118

Intervention type: OTHER
Intervention: a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient
Description: a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
Study: NCT06645496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of ehealth literacy
Description: All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study (RO_eHEALTH I). If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
Study: NCT04979156

Intervention type: PROCEDURE
Intervention: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
Description: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
Study: NCT05655624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed lip Breathing along Mat Pilates
Description: Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pursed lip breathing without Mat Pilates Training
Description: Control Group will be treated pursed lip breathing without Mat Pilates Training
Study: NCT05470218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Liquid mixed meal with different amounts of protein and leucine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Liquid mixed meal with different amounts of protein and leucine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Liquid mixed meal with different amounts of protein and leucine
Study: NCT05095233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)
Description: YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Min Plan Tool
Description: Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
Study: NCT06410625

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FLT PET imaging
Description: Evaluation of response to chemotherapy with FLT PET imaging
Study: NCT04739189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Con : control condition without exercise / rest condition
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Def-EX : Condition with an exercise-induced energy deficit
Description: Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Def-EI : Condition with an energy-restriction energy deficit
Description: Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
Study: NCT06540248

Intervention type: DEVICE
Intervention: Ialuadapter
Description: minimally invasive syringe device for bladder catherization
Study: NCT04939324

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples at 2 sites: peripheral vein and tumor-draining vein
Description: D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)
Study: NCT05382871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)
Description: intramuscular injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)
Description: intramuscular injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)
Description: intramuscular injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)
Description: intramuscular injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: intramuscular injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: intramuscular injection in the deltoid muscle
Study: NCT06304597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imfinzi
Description: Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
Study: NCT06331195

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phytosterol
Description: Placebo of phytosterol, in the same quantity of the active phytosterol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo phytosterol
Description: Placebo of phytosterol, in the same quantity of the active phytosterol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo krill oil
Description: Placebo of krill oil, in the same quantity of the active krill oil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo krill oil
Description: Placebo of krill oil, in the same quantity of the active krill oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
Study: NCT06004492

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: blended learning program
Description: blended learning program: 8 hours of workshops and four months of practical learning on technology platforms.
Study: NCT06647875

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complementary Feeding Education
Description: This training program has been designed in accordance withWHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age. The training will be delivered both in-person and via tablet, and will be supported by infographics and visuals created using WHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age and the Basic Information for Families on Child Health and Safety in the First 5 Years booklet published by the Child Health Association, specifically the section on Healthy Eating. At the end of the training, participants will be provided with a booklet containing the Healthy Eating section of the Child Health Association's booklet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary Feeding Education
Description: This training program has been designed in accordance withWHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age. The training will be delivered both in-person and via tablet, and will be supported by infographics and visuals created using WHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age and the Basic Information for Families on Child Health and Safety in the First 5 Years booklet published by the Child Health Association, specifically the section on Healthy Eating. At the end of the training, participants will be provided with a booklet containing the Healthy Eating section of the Child Health Association's booklet.
Study: NCT05673096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT
Description: Paediatric Autism Communication Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MAU
Description: Management as usual
Study: NCT05805085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Hydrogel Daily Disposable Toric Contact Lens for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Silicone Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
Study: NCT05024981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videographic feedback
Description: Twice a week during his classic re-education sessions, the patient will be filmed for 1 minute. After transferring the video to a tablet, he will watch the video once and decide what he wants to correct. During the second viewing, he will analyse his walk, the therapist being present to provide additional information. Finally, the patient will apply his analysis while being filmed and will compare the possible differences between the 2 videos. Depending on the time available, the patient may have to repeat the recordings, analyses and exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classic reeducation
Description: The patient will benefit twice a day for 30 minutes from re-education sessions.
Study: NCT06648954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multisite HD-tDCS
Description: 5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tDCS
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
Study: NCT06077149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine
Description: All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV vaccine
Description: All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally
Study: NCT04939675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100mg
Description: Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500mg
Description: Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LamoTRIgine 50mg
Description: Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
Study: NCT05329051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: intramuscular injection
Study: NCT06055244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Subjects will be give amantadine 100 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine
Description: Subjects will be give amantadine 100 mg twice daily.
Study: NCT05970016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCC1727 tablet
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
Study: NCT06074887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transtheoretical model-based intervention
Description: Pretest data are collected for patients in the intervention group in a face-to-face interview in the hospital setting.~The training prepared according to the behavior change phase will be conducted one week later in the patients' home environment and the required data will be collected.~In the fourth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the eighth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the twelfth week of the study, the patient will be visited at home and final tests will be collected.
Study: NCT05406505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: patients will receive once daily dapagliflozin 10 mg orally in addition to standard care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo and standard care.
Study: NCT06361303

Intervention type: DEVICE
Intervention: SNOO Bassinet
Description: This is a non-interventional, prospective observational and descriptive active surveillance study of a cohort of individuals who have purchased or rented a SNOO for use with their infant.
Study: NCT05680506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education will be given in form videos,pictures, stories and metaphors for 2 times per week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises
Study: NCT04546113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of ropivacapine 3,75 mg/ml/side
Description: Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side
Description: Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side